1. |
Angiotensin II receptor antagonists not yet the ELITE |
|
Inpharma Weekly,
Volume &NA;,
Issue 1237,
2000,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
2. |
A lucky break for patients with osteoporosis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1237,
2000,
Page 3-4
Mark Greener,
Preview
|
|
摘要:
Osteoporosis appears to be more aggressive, and progress more quickly, than many clinicians previously thought, according to new data released during the UK National Osteoporosis Society's (NOS) Conference [Bath, UK; April 2000]. Delegates also heard that risedronic acid [risedronate; 'Actonel'] is the first osteoporosis treatment proven to reduce fracture risk within this period in a large group of patients. In light of recent question marks concerning the cardiovascular benefits of hormone replacement therapy (HRT), a leading specialist suggests that the findings might redefine the relative roles of current antiosteoporosis treatments.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
3. |
Travellers urged to get hepatitis vaccinations |
|
Inpharma Weekly,
Volume &NA;,
Issue 1237,
2000,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
4. |
Goserelin better value than danazol in dysfunctional uterine bleeding? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1237,
2000,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
5. |
Temozolomide cost effective for metastatic melanoma |
|
Inpharma Weekly,
Volume &NA;,
Issue 1237,
2000,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
6. |
New developments in cancer therapy: molecularly targeted agents |
|
Inpharma Weekly,
Volume &NA;,
Issue 1237,
2000,
Page 7-8
Ruth Williams,
Carmen Innes,
Preview
|
|
摘要:
Mammalian cell cycle control and signal transduction pathways are usually perturbed in the genesis and progression of cancer, causing the cancerous cell to be locked into an active proliferative state. Increased understanding of these processes has led to the development of pharmaceutical agents designed to intervene at specific molecular steps involved in carcinogenesis. These agents include inhibitors of cell cycle progression, inhibitors of tyrosine kinase receptors and inhibitors of other molecules involved in intracellular signal transduction such as farnesyltransferase. It is hoped that such agents will, due to their specificity, be both more effective and less toxic than conventional nonspecific chemotherapy. At the 91st Annual Meeting of the American Association for Cancer Research (AACR) [San Francisco, US; April 2000], some encouraging results in this field were presented, including Glaxo Wellcome's GW 8510, a potential preventative treatment for chemotherapy-induced alopecia, data from Roche's new cell cycle inhibitor RO 317453 and an update on Novartis' tyrosine kinase inhibitor STI 571.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1237,
2000,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
8. |
New approach to toxic shock shows promise |
|
Inpharma Weekly,
Volume &NA;,
Issue 1237,
2000,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1237,
2000,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
10. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1237,
2000,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|